Ophthalmologists must work with oncologists to understand and mitigate ocular surface adverse events caused by oncologic therapeutics, according to a presentation at Real World Ophthalmology.
Antibody-drug conjugate (ADC) therapy is a promising approach in cancer treatment that entails linking cytotoxic drugs to antibodies for targeted delivery. However, ADCs have demonstrated an ocular surface adverse event profile that may include symptoms such as blurred vision, tearing, foreign body sensation, photophobia and pain along with signs such as epithelial changes, topographical changes,